Phio Pharmaceuticals

Company snapshot

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biopharmaceutical company whose proprietary INTASYL siRNA technology makes our bodies’ immune cells more effective in killing tumor cells. INTASYL is the only self-delivering siRNA technology focused on immuno-oncology therapeutics. Phio was co-founded by a Nobel Laureate for discovery of RNAi. This discovery was leveraged to develop IN

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 39 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Phio Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Phio Pharmaceuticals.

1. May 23, 2026 Clinical update

   DP CD8 TIL — Phase 1

2. May 23, 2026 Clinical update

   PH-762 — Phase 1

3. Mar 12, 2024 Patent grant

   Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1

4. May 2, 2023 Patent grant

   Bryoid compositions, methods of making and use thereof

5. Feb 21, 2023 Patent grant

   RNA interference in ocular indications

View all clinical trial activity →

• What is Phio Pharmaceuticals?

  Phio Pharmaceuticals is a pharma organization headquartered in King of Prussia, USA. It trades on NYSE under ticker PHIO. Primary therapeutic focus areas include HNSCC, Squamous Cell Carcinoma of the Skin. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 39 pate

• Is Phio Pharmaceuticals publicly traded?

  Yes. Phio Pharmaceuticals is listed with ticker PHIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Phio Pharmaceuticals develop or market?

  No drug profiles are currently linked to Phio Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for Phio Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Phio Pharmaceuticals focus on?

  Phio Pharmaceuticals focuses on HNSCC, Squamous Cell Carcinoma of the Skin based on our analysis of their pipeline programs and drug development activities.